ASH Annual Meeting and Exposition | Conference

Dual Transplant Prevails in Patients With Newly Diagnosed Myeloma

December 19th 2016

Patients with newly diagnosed multiple myeloma had significant improvement in progression-free survival when treated with dual versus single autologous stem-cell transplant.

Expanded Access Data Confirm Safety, Efficacy of Ruxolitinib in Myelofibrosis

December 16th 2016

Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib (Jakafi) in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.

Addition of Daratumumab Triples Increase in MRD Conversion in Relapsed Myeloma

December 16th 2016

The addition of daratumumab to standard-of-care regimens tripled the increase in conversion to negative minimal residual disease status in the treatment of patients with relapsed/refractory multiple myeloma.

Elotuzumab Triplet Yields High Response Rate in High-Risk Smoldering MM

December 12th 2016

The combination of elotuzumab, lenalidomide, and dexamethasone has excellent activity and is well-tolerated in the treatment of high-risk smoldering multiple myeloma (SMM), providing hope that it can delay or even halt progression to MM.

More Randomized Data Support Pacritinib Efficacy in Myelofibrosis

December 8th 2016

Patients with myelofibrosis and thrombocytopenia had significantly greater reductions in spleen volume and symptoms when treated with the multikinase inhibitor pacritinib, compared with the best available therapy.

JCAR017 Shows Promising Activity, Mild Toxicity in CD19+ Lymphoma

December 8th 2016

The CD19-directed CAR T-cell therapy JCAR017 demonstrated a 60% complete response rate in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma.

Multiple Myeloma Transplant Trial Shows No Extra Benefit with Additions to Standard Therapy

December 8th 2016

According to the results of the phase III StaMINA trial evaluating posttransplant therapy in multiple myeloma, a second a round of chemotherapy or stem cell transplant does not improve progression-free survival or overall survival compared with the current standard course of treatment alone.

Nivolumab-Brentuximab Vedotin Combo Active and Safe in Relapsed Hodgkin Lymphoma

December 8th 2016

Early data from a phase I/II study suggest that the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) may be an active and well-tolerated outpatient regimen in patients with relapsed/refractory classical Hodgkin lymphoma after failure of standard frontline chemotherapy.

High Response Rate With Venetoclax in Relapsed/Refractory CLL

December 8th 2016

Two thirds of patients with chronic lymphocytic leukemia (CLL) that progressed on B-cell receptor pathway inhibitors had objective responses to treatment with venetoclax, results of a small open-label trial showed.

Dr. Jackson on Lenalidomide as a Highly-Effective Maintenance Therapy in Myeloma

December 7th 2016

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.

KTE-C19 Leads to High Response Rates in Refractory NHL

December 7th 2016

Almost 80% of patients with treatment-refractory non-Hodgkin lymphoma had objective responses following treatment with KTE-C19, a chimeric antigen receptor T-cell therapy targeting CD19.

Ibrutinib Shows Promise in Treating GVHD After Stem Cell Transplant

December 7th 2016

An FDA-approved blood cancer drug has demonstrated encouraging findings, including an overall response rate of 67%, in treatment of patients with chronic graft-versus-host-disease that was not resolved by corticosteroids.

Dr. Woyach on a Study Combining MOR208 With Lenalidomide for the Treatment of CLL

December 7th 2016

Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study examining the use of MOR208 combined with lenalidomide (Revlimid) for the treatment of chronic lymphotic leukemia (CLL) during the American Society of Hematology (ASH) Annual Meeting.

Subcutaneous Daratumumab Safe, Effective in Myeloma

December 6th 2016

Subcutaneous delivery of daratumumab was well tolerated with comparable efficacy to the FDA-approved intravenous dose in patients with relapsed/refractory multiple myeloma.

Venetoclax Highly Effective With Bortezomib/Dexamethasone for Multiple Myeloma

December 6th 2016

Adding venetoclax to bortezomib and dexamethasone showed very promising efficacy and acceptable safety for patients with relapsed/refractory multiple myeloma.

Selinexor Active in Heavily Pretreated Myeloma

December 6th 2016

Selinexor, in combination with dexamethasone, induced a response rate of 20.5% (n = 16) among 78 heavily pretreated patients with relapsed/refractory multiple myeloma, according to results from the phase IIb STORM trial presented at the 2016 ASH Annual Meeting.

Dr. Gisslinger on a Study Comparing Ropeginterferon Alfa-2b to Hydroxyurea in PV

December 6th 2016

Heinz Gisslinger, MD, Medical University of Vienna, discusses the phase III PROUD-PV study, which evaluated ropeginterferon alfa-2b (P1101) for the treatment of polycythemia vera (PV) during the American Society of Hematology (ASH) Annual Meeting.

KTE-C19 Response Rates Spark FDA Submission for Aggressive Lymphomas

December 6th 2016

Treatment with the CD19-directed CAR T-cell therapy KTE-C19 showed a complete remission rate of 73% for patients with aggressive, chemorefractory primary mediastinal B-cell lymphoma and transformed follicular lymphoma.

Early Study Signals Promising Role for Venetoclax in Treatment of Relapsed CLL

December 6th 2016

Adding the oral BCL-2 inhibitor venetoclax (Venclexta) to obinutuzumab (Gazyva) and ibrutinib (Imbruvica) in patients with relapsed/refractory chronic lymphocytic leukemia is safe and is demonstrating encouraging signs of efficacy.

Ibrutinib Regimen Induces 100% Induction Response in CLL

December 6th 2016

An induction regimen of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) after bendamustine debulking induced a 100% response rate in patients with chronic lymphocytic leukemia.